Urodynamic standardization in a large‐scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction
- 25 June 2010
- journal article
- research article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 29 (5) , 741-747
Abstract
Aims: To present the methodology, standardization techniques, and results from post hoc test–retest reproducibility analyses for a large, placebo‐controlled, multicenter trial, employing urodynamic studies (UDS) to assess the impact of daily tadalafil on men with lower urinary tract symptoms (LUTS) with or without benign prostatic obstruction (BPO).Methods: UDS implemented International Continence Society (ICS) Good Urodynamic Practice guidelines and standardized urodynamic and LUTS terminology. Further standardization procedures included: equipment calibration; a detailed procedure manual and centralized training; and implementation of a central reader. Measures included: monitoring of invalid studies, comparison of actual versus expected standard deviation (SD) for primary outcome (detrusor pressure at maximum urinary flow rate [pdetQmax]), and test–retest reproducibility of the placebo arm at baseline and endpoint.Results: Two hundred men with moderate to severe LUTS (baseline IPSS ≥13) at 20 sites were randomized to receive either tadalafil 20 mg or placebo. All men underwent non‐invasive uroflow and pressure‐flow studies. Numbers of invalid studies at baseline and endpoint were 9.3% and 0.6%, respectively. Variability of pdetQmax was lower than anticipated based on actual versus expected SD of 15 and 30, respectively. Correlation coefficients were very good for pressure‐flow parameters including pdetQmax (r = .83).Conclusions: Multicenter clinical trials using urodynamic outcomes require additional standardized procedures to limit inter‐site variability. By implementing centralized training with a detailed procedure manual and use of a central reader, we were able to limit common difficulties arising in multicenter clinical trials, as well as demonstrate good test–retest reproducibility of pressure flow measures. Neurourol. Urodynam. 29:741–747, 2010.Keywords
Funding Information
- Eli Lilly and Company
This publication has 9 references indexed in Scilit:
- The Immediate and 6-mo Reproducibility of Pressure–Flow Studies in Men with Benign Prostatic EnlargementEuropean Urology, 2007
- Process for Development of Multicenter Urodynamic StudiesUrology, 2007
- Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Men With Bladder Outlet ObstructionJournal of Urology, 2006
- Quality control in urodynamics: a review of urodynamic traces from one centreBJU International, 2003
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure‐flow studies**Neurourology and Urodynamics, 2002
- Urodynamic protocol and central review of data for clinical trials in lower urinary tract dysfunctionBJU International, 2000
- Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding functionBJU International, 1999
- Repeated pressure-flow studies in the evaluation of bladder outlet obstruction due to benign prostatic enlargementNeurourology and Urodynamics, 1998